Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has submitted an application to the European Medicines Agency (EMA) to modify the Phase 3 clinical trial plan (Part 1 & 2) for ‘CT-P55’, a biosimilar to Cosentyx, following adjustments to its regulatory strategy and patient sample size.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Application for Modification of Phase 3 Clinical Trial Plan in Europe for CT-P55 (Cosentyx Biosimilar) (Part 1 & Part 2) (Major Management Matters)
- Clinical Phase & Target Indication: Global Phase 3 Clinical Trial / Plaque psoriasis
- Application Date & Regulatory Body: October 27, 2025 (Local time) / European Medicines Agency (EMA)
- Clinical Trial Registration Number: EU CT number: 2024-513348-27-00
- Reason for Modification & Key Details:
- Application submitted to adjust sample size following changes in global approval strategy
- Dual submission for Part 1 (clinical design and methodology) and Part 2 (trial sites and execution) pursuant to EU CTR rules
- Trial Purpose & Design:
- Purpose: To compare efficacy and safety between CT-P55 and reference product Cosentyx in moderate-to-severe plaque psoriasis patients to demonstrate biosimilarity
- Duration: 56 weeks (Design: Randomized, active-controlled, double-blind, Phase 3)
- Number of Subjects: Temporarily deferred from public disclosure under business confidentiality until final Part 1 & 2 approval
- Risk Disclosure: The statistical success rate for clinical trial drugs obtaining final regulatory approval is approximately 10%, and commercialization plans remain subject to change or termination based on trial outcomes.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of EMA Approval for Modified Phase 3 Trial Plan (Part 1 & 2) and Disclosure of Deferred Sample Size
This disclosure details Celltrion’s submission of a modified Phase 3 trial protocol for CT-P55 to the EMA reflecting an adjusted approval strategy, making it important to monitor the final regulatory approval of both Part 1 and Part 2. Obtaining full approval ensures the trial can proceed as planned without timeline disruptions. Regulatory approvals and the unmasking of the deferred sample size count can be verified through future regulatory disclosures regarding ‘Approval of Modified Phase 3 Clinical Trial Plan for CT-P55’ or upcoming periodic reports (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
